Marwan Sabbagh, MD, FAAN, CCRI, is a neurologist and the director of the Alzheimer’s Disease and Memory Disorders Division at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix. He is board certified by the American Board of Psychiatry and Neurology.
Dr. Sabbagh’s expertise includes Alzheimer’s disease and dementia. He is a member of the American Academy of Neurology and Arizona Geriatric Society.
Dr. Sabbagh received his medical degree from the University of Arizona College of Medicine in Tucson. He completed his internship at Good Samaritan Regional Medical Center. Dr. Sabbagh completed his residency at Baylor College of Medicine in Houston in neurology and completed his fellowship in geriatric neurology and dementia at the University of California – San Diego, School of Medicine.
Dr. Sabbagh’s research interests include clinical trials of medications to treat or prevent Alzheimer’s and research on Down syndrome.
For more information or to request an appointment, please call (480) 787-2284.
Fax: (602) 406-6261
- Fellowship, University of California – San Diego School of Medicine, Geriatric Neurology and Dementia, 1995-1997
- Residency, Baylor College of Medicine, Neurology, 1992-1995
- Internship, Good Samaritan Regional Medical Center, Internal Medicine, 1991-1992
- MD, University of Arizona College of Medicine, 1991
- BA, University of California – Berkeley, 1987
- American Academy of Neurology
- Arizona Geriatric Society
- Fellow of the American Academy of Neurology, 2004
- Healthcare Hero Finalist, Arizona Business Journal, 2004
- Dystonia Doctor of Excellence, San Diego County, 2000
- Co-recipient, Peter F. Drucker Award, 1998
- Travel Fellowship Award, American Neurological Association, 1996
- Finalist, Allistair Karmody Award, 1991
- Student Representative to the Western Federation of Clinical Research, University of Arizona, 1990
- Student Summer Fellow, Arizona Cancer Society, 1988
- Serrano GE, Intorcia A, Carew J, Chiarolanza G, Hidalgo JA, Sue LI, Dugger BN, Saxon-LaBelle M, Filon J, Scroggins A, Pullen J, Fornwalt BE, Scott S, Sabbagh MN, Adler CH, Akiyama H, Beach TG. Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases. J Neuropathol Exp Neurol. Sep 2015;74(9):934-942.
- Postuma RB, Adler CH, Dugger BN, Hentz JG, Shill HA, Driver-Dunckley E, Sabbagh MN, Jacobson SA, Belden CM, Sue LI, Serrano G, Beach TG. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord. Sep 2015;30(10):1413-1417.
- Mu L, Chen J, Sobotka S, Nyirenda T, Benson B, Gupta F, Sanders I, Adler CH, Caviness JN, Shill HA, Sabbagh M, Samanta JE, Sue LI, Beach TG, Arizona Parkinson’s Disease C. Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson’s Disease Patients. Dysphagia. Aug 2015;30(4):404-417.
- Malek-Ahmadi M, Sabbagh MN. Development and Validation of the Alzheimer’s Questionnaire (AQ). J Nat Sci. May 2015;1(5):e104.
- Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. Mar 2015;72(3):287-294.
- Budolfson K, Malek-Ahmadi M, Belden CM, Powell J, Davis K, Jacobson S, Sabbagh MN. Neuropsychological Correlates of the Alzheimer’s Questionnaire. J Alzheimers Dis. Mar 3 2015.
- Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. Aug 1 2015:1-6.
- Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. Oct 2015;24(10):1355-1360.
- Tsai A, Malek-Ahmadi M, Kahlon V, Sabbagh MN. Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease. J Alzheimers Dis Parkinsonism. May 30 2014;4(4).
- Richards D, Sabbagh MN. Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain. Neurol Ther. Dec 2014;3(2):79-88.